Injosetron (Palonosetron)

Palonosetron works by selectively binding to the serotonin 5‑HT3 receptor on peripheral and central neurons, blocking serotonin from activating the receptor. This inhibition stops the emetic signaling cascade in the chemoreceptor trigger zone and gastrointestinal tract, thereby preventing the sensation of nausea and the act of vomiting.

The dose of Injosetron is determined by the prescribing clinician based on the specific chemotherapy regimen or surgical procedure. The prescriber selects the appropriate intravenous amount and timing to achieve optimal antiemetic protection, following local guidelines and product labeling.

The pregnancy safety category for palonosetron is not definitively established. Injosetron should be used during pregnancy or lactation only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after careful consideration by the treating physician.

To order Injosetron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with import documentation.

Injosetron (palonosetron) has a longer plasma half‑life and higher receptor affinity than first‑generation 5‑HT3 antagonists such as ondansetron, providing extended protection against delayed chemotherapy‑induced nausea. It is generally well tolerated, but clinicians still consider individual patient risk factors and may combine it with other antiemetics for optimal control.

Injosetron should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and ensure proper cold‑chain conditions during transport.

Injosetron is administered as an intravenous injection or infusion. The healthcare professional prepares the solution according to the product label and delivers it through a peripheral or central IV line, typically as a single dose given before chemotherapy or surgery, following institutional protocols.

Serious adverse reactions to Injosetron include anaphylaxis, severe allergic responses, QT interval prolongation that can lead to cardiac arrhythmias, and rare cases of serotonin syndrome when combined with other serotonergic agents. Prompt recognition and medical intervention are essential if these events occur.

Injosetron is contraindicated in patients with known hypersensitivity to palonosetron or any component of the formulation. Caution is also advised for individuals with significant cardiac conduction abnormalities, prolonged QT interval, or those receiving other drugs that markedly affect cardiac repolarization.